Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Malignant Lymphoma

Free Subscription Articles published in Blood Retrieve available abstracts of 306 articles: HTML format

Single Articles

September 2026
1. ABRAMSON JS, Siddiqi T, Gordon LI, Lunning M, et al
   Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study.
   Blood. 2026;148:1388-1393.
   PubMed     Abstract available
   
   
   
2. KRUPKA JA, Pott C, Hodson DJ
   Technical Considerations in the choice and use of ctDNA for Large B-cell lymphoma (LBCL).
   Blood. 2026 Sep 3:blood.2026033074. doi: 10.1182/blood.2026033074.
   PubMed     Abstract available
   
   
   
3. NITHAGON P, Saksena A
   Classic Hodgkin lymphoma showing interfollicular and intrasinusoidal involvement.
   Blood. 2026;148:1364.
   PubMed    
   
   
   
4. MAGNANO L, Lopez-Guillermo A, Maurer MJ
   A framework to challenge the dogma of incurability in follicular lymphoma.
   Blood. 2026 Sep 2:blood.2026035096. doi: 10.1182/blood.2026035096.
   PubMed     Abstract available
   
   
   August 2026
5. 
   Casulo C, Dixon JG, Le-Rademacher J, et al; FLASH (Follicular Lymphoma Analysis of Surrogacy Hypothesis) Group. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139(1
   Blood. 2026;148:1067.
   PubMed    
   
   
   
6. REJESKI K, Banerjee R, Hill JA
   How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies.
   Blood. 2026;148:927-938.
   PubMed     Abstract available
   
   
   
7. 
   Abro B, Maurer MJ, Habermann TM, et al. Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis. Blood. 2024;144(19):2063-2066.
   Blood. 2026;148:914.
   PubMed    
   
   
   
8. MARTIN P
   How soon is now for new treatments for mantle cell lymphoma?
   Blood. 2026;148:641-642.
   PubMed    
   
   
   
9. ALLBEE AW, Sadigh S
   Disseminated cryptococcal lymphadenitis mimicking lymphoma and masked by prozone effect.
   Blood. 2026;148:794.
   PubMed    
   
   
   
10. 
    Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma, Blood. 2008;111(4):2230-2237.
    Blood. 2026;148:795.
    PubMed    
    
    
    
11. BUDDE LE, Kamdar M, Assouline SE, Chavez JC, et al
    Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.
    Blood. 2026;148:682-692.
    PubMed     Abstract available
    
    
    July 2026
12. 
    Domostegui A, Peddigari S, Mercer CA, et al. Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death. Blood. 2021;137(24):3351-3364.
    Blood. 2026;148:640.
    PubMed    
    
    
    
13. POGGIO T, Grassel L, Andrieux G, Gomez Martinez AM, et al
    CD4+ T cells orchestrate the immune response to ALK-positive T-cell lymphoma.
    Blood. 2026 Jul 28:blood.2026033240. doi: 10.1182/blood.2026033240.
    PubMed     Abstract available
    
    
    
14. ARAUJO-AYALA F, Ros M, Alexandru R, Mateos-Jaimez J, et al
    CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma.
    Blood. 2026 Jul 22:blood.2025032663. doi: 10.1182/blood.2025032663.
    PubMed     Abstract available
    
    
    
15. 
    Chihara D, Dores GM, Flowers CR, Morton LM. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood. 2021;138(9):785-789.
    Blood. 2026;148:389.
    PubMed    
    
    
    
16. CHIHARA D, Westin JR
    The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design.
    Blood. 2026 Jul 6:blood.2026034393. doi: 10.1182/blood.2026034393.
    PubMed     Abstract available
    
    
    
17. WANG M, Hoffmann MS, Wrobel T, Trneny M, et al
    First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients >/=65 years or with TP53 mutations.
    Blood. 2026 Jul 1:blood.2025032833. doi: 10.1182/blood.2025032833.
    PubMed     Abstract available
    
    
    June 2026
18. FALCONER J
    The RELEVANCE of long-term follow-up in follicular lymphoma.
    Blood. 2026;147:2993-2994.
    PubMed    
    
    
    
19. SPECHT L
    Less is more in primary cutaneous indolent B-cell lymphoma.
    Blood. 2026;147:2992-2993.
    PubMed    
    
    
    
20. 
    Diefenbach CS, Jegede O, Wang V, et al. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026;147(18):2041-2052.
    Blood. 2026;147:3123.
    PubMed    
    
    
    
21. KIM WS, Kim SJ, Yoon DH, Cho H, et al
    Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01).
    Blood. 2026 Jun 12:blood.2025032636. doi: 10.1182/blood.2025032636.
    PubMed     Abstract available
    
    
    
22. 
    Grabow S, Delbridge ARD, Valente LJ, Strasser A. MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice. Blood. 2014;124(26):3939-3946.
    Blood. 2026;147:2988.
    PubMed    
    
    
    
23. YU C, Holloman M, Kim A, Chang Y, et al
    Differential role of CREBBP missense and truncating mutations in germinal center development and lymphomagenesis.
    Blood. 2026;147:2713-2727.
    PubMed     Abstract available
    
    
    May 2026
24. GOBEL C, Niccolai R, Gregoricchio S, de Groot MHP, et al
    DOT1L Shapes ncPRC1-Target Gene Repression to Maintain Germinal Center B Cell Identity of Diffuse Large B cell Lymphoma.
    Blood. 2026 May 29:blood.2025031615. doi: 10.1182/blood.2025031615.
    PubMed     Abstract available
    
    
    
25. HU S, Qin Y, Yi HM, Huang YH, et al
    N6-methyladenosine reader IGF2BP2 in T-cell lymphoma.
    Blood. 2026 May 21:blood.2026034186. doi: 10.1182/blood.2026034186.
    PubMed     Abstract available
    
    
    
26. LOSSOS IS
    MRD testing in Hodgkin lymphoma: filling the knowledge gaps.
    Blood. 2026;147:2159-2160.
    PubMed    
    
    
    
27. AHMED AA, Tadros S
    Classic Hodgkin lymphoma with IGH::CCND1 rearrangement: evidence of clonal relation to preceding mantle cell lymphoma.
    Blood. 2026;147:2278.
    PubMed    
    
    
    
28. VANNUCCHI AM, Patel JL, Kiladjian JJ
    Myeloid/lymphoid neoplasms with FGFR1 rearrangement and pemigatinib.
    Blood. 2026;147:2171-2175.
    PubMed     Abstract available
    
    
    
29. HEGER JM, Mattlener J, Kaul H, Ferdinandus J, et al
    MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.
    Blood. 2026;147:2194-2202.
    PubMed     Abstract available
    
    
    
30. DAVIDSON-SWINTON HR, Iyer S, Kolchinski A, Salem JA, et al
    Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.
    Blood. 2026;147:2226-2237.
    PubMed     Abstract available
    
    
    April 2026
31. TOBIN JWD, Gandhi MK
    SIGN of the times: DC-SIGN and the follicular lymphoma niche.
    Blood. 2026;147:2025-2026.
    PubMed    
    
    
    
32. 
    Strati P, Ahmed S, Furqan F, et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021;137(23):3272-3276.
    Blood. 2026;147:2157.
    PubMed    
    
    
    
33. BARIBOLOKA KT, Serrano-Saenz S, Savcigil DP, Spoeck S, et al
    Expression of cFLIP in B cells is essential for diffuse large B-cell lymphoma pathogenesis.
    Blood. 2026 Apr 23:blood.2026033320. doi: 10.1182/blood.2026033320.
    PubMed     Abstract available
    
    
    
34. SCHORB E
    Mapping risk and therapy in secondary CNS lymphoma.
    Blood. 2026;147:1783-1784.
    PubMed    
    
    
    
35. STEVENSON FK, Stamatopoulos K
    The singularity of IGHV4-34 links infection, autoimmunity, and B-cell tumors.
    Blood. 2026;147:1793-1803.
    PubMed     Abstract available
    
    
    
36. VODICKA P, El-Galaly TC, Prochazka V, Flowers CR, et al
    Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy.
    Blood. 2026 Apr 14:blood.2026033090. doi: 10.1182/blood.2026033090.
    PubMed     Abstract available
    
    
    
37. AOKI T, Kuruvilla J
    Targeted therapy in early-stage classical Hodgkin lymphoma.
    Blood. 2026;147:1655-1657.
    PubMed    
    
    
    
38. SCHROERS-MARTIN JG
    Digging deep for the roots of lymphoma.
    Blood. 2026;147:1657-1658.
    PubMed    
    
    
    
39. ROBERTZ AS, Buhnen I, Meissner J, Trautmann-Grill K, et al
    Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL Trial.
    Blood. 2026 Apr 2:blood.2025031809. doi: 10.1182/blood.2025031809.
    PubMed     Abstract available
    
    
    March 2026
40. GOWER N, Feugier P, Westin JR, Schiano de Colella JS, et al
    Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.
    Blood. 2026 Mar 31:blood.2026033126. doi: 10.1182/blood.2026033126.
    PubMed     Abstract available
    
    
    
41. 
    Ronceray L, Huibers MHW, Reutter K, et al. High-grade/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition. Blood. 2026;147(2):209-214.
    Blood. 2026;147:1504.
    PubMed    
    
    
    
42. 
    Jaye DL, Feldman AL. ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma. Blood. 2023;141(17):2160.
    Blood. 2026;147:1504.
    PubMed    
    
    
    
43. KAMDAR M, Bartlett NL
    From Breakthroughs to Blueprints: Evolving Evidence and Future Directions in Relapsed and Refractory Large B-Cell Lymphoma.
    Blood. 2026 Mar 23:blood.2025030859. doi: 10.1182/blood.2025030859.
    PubMed     Abstract available
    
    
    
44. 
    HOD08 for low-risk pediatric Hodgkin lymphoma.
    Blood. 2026;147:1381.
    PubMed    
    
    
    
45. KAULEN LD, Nayak L, Karschnia P, Kraai I, et al
    Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study.
    Blood. 2026 Mar 17:blood.2025031869. doi: 10.1182/blood.2025031869.
    PubMed     Abstract available
    
    
    
46. OERTEL M, Dabaja BS, Gorlich D, Thomas BR, et al
    Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis.
    Blood. 2026 Mar 13:blood.2025032050. doi: 10.1182/blood.2025032050.
    PubMed     Abstract available
    
    
    
47. FELDMAN AL, Dasari S, Rimsza LM, Scott DW, et al
    Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.
    Blood. 2026;147:1199-1214.
    PubMed     Abstract available
    
    
    
48. ZAMMAR G, Cheah CY
    Pretransplant promise for PD-1 in Hodgkin lymphoma.
    Blood. 2026;147:1015-1017.
    PubMed    
    
    
    
49. RHEIN S, Cakmak-Gorur N, Grunert C, Al-Tabatabaee S, et al
    A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.
    Blood. 2026;147:1058-1069.
    PubMed     Abstract available
    
    
    
50. CROMBIE JL, Ahmed S, Frigault MJ, Hunter BD, et al
    Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
    Blood. 2026 Mar 3:blood.2025031733. doi: 10.1182/blood.2025031733.
    PubMed     Abstract available
    
    
    February 2026
51. LI X, Liu M, Shi Q, Du ZS, et al
    CSNK1E Sustains Stem-like Drug Persistence in Diffuse Large B-cell Lymphoma.
    Blood. 2026 Feb 27:blood.2025031156. doi: 10.1182/blood.2025031156.
    PubMed     Abstract available
    
    
    
52. MARCOUX P, Gava F, Tosolini M, Gravelle P, et al
    Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed/Refractory B-NHL.
    Blood. 2026 Feb 26:blood.2025031309. doi: 10.1182/blood.2025031309.
    PubMed     Abstract available
    
    
    
53. STEWART J, Damania B
    Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation.
    Blood. 2026;147:848-862.
    PubMed     Abstract available
    
    
    
54. DOWLING MR, Cliff ERS, Jeffrey A, Cashion C, et al
    Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.
    Blood. 2026 Feb 17:blood.2025032307. doi: 10.1182/blood.2025032307.
    PubMed     Abstract available
    
    
    
55. YENWONGFAI LN, Francischetti IMB
    Follicular lymphoma transformed to classic Hodgkin lymphoma.
    Blood. 2026;147:800.
    PubMed    
    
    
    
56. SORIAL MN, Malpica Castillo LE, Chiattone C, Julia E, et al
    Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.
    Blood. 2026;147:755-767.
    PubMed     Abstract available
    
    
    
57. DIEFENBACH C, Jegede O, Wang V, Ansell SM, et al
    A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma.
    Blood. 2026 Feb 9:blood.2025029546. doi: 10.1182/blood.2025029546.
    PubMed     Abstract available
    
    
    
58. DORANDO HK, Andrews JM, Khatavkar OU, Borcherding N, et al
    Multi-omic Study of Cutaneous T-Cell Lymphoma Reveals Single Cell Clonal Evolution in Progression and Therapy Resistance.
    Blood. 2026 Feb 9:blood.2025029012. doi: 10.1182/blood.2025029012.
    PubMed     Abstract available
    
    
    
59. 
    Liu X, Zhang Q, Guo H, Pan Q, Zhou K. Bendamustine, gemcitabine, and vinorelbine (BeGEV) regimen followed by ASCT induces durable remissions in PD-(L)1 inhibitor-resistant refractory/relapsed classical Hodgkin lymphoma: a single-center, long-term stud
    Blood. 2026;147:703.
    PubMed    
    
    
    January 2026
60. URANO Y, Satou A
    Primary colonic T-cell lymphoma with a TFH phenotype, favoring extranodal TFH lymphoma, angioimmunoblastic type.
    Blood. 2026;147:602.
    PubMed    
    
    
    
61. CHIODIN G, Tatterton DJ, Rock PJ, Del Rio L, et al
    DC-SIGN Binding to the Surface Ig Oligomannose-type Glycans Promotes Follicular Lymphoma Cell Adhesion and Survival.
    Blood. 2026 Jan 20:blood.2025030049. doi: 10.1182/blood.2025030049.
    PubMed     Abstract available
    
    
    
62. THOMPSON C, Trneny M, Morschhauser F, Salles G, et al
    PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.
    Blood. 2026;147:254-265.
    PubMed     Abstract available
    
    
    
63. FLERLAGE JE, Feraco AM MD, MMSc, Zhou Y, Zheng Y MS, et al
    Dose-dense chemotherapy enables elimination of RT for majority of low-risk pediatric Hodgkin lymphoma: PHC study HOD08.
    Blood. 2026 Jan 13:blood.2025029535. doi: 10.1182/blood.2025029535.
    PubMed     Abstract available
    
    
    
64. ARMAND P
    Introduction to a review series on marginal zone lymphoma: reclaiming the afterthought.
    Blood. 2026;147:95.
    PubMed    
    
    
    
65. LAURENT C, Bertoni F
    The biology of marginal zone lymphoma subtypes: challenge and relevance of classification.
    Blood. 2026;147:105-114.
    PubMed     Abstract available
    
    
    
66. ALDERUCCIO JP, Baggio D, Han S, Ghione P, et al
    Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.
    Blood. 2026 Jan 5:blood.2025031455. doi: 10.1182/blood.2025031455.
    PubMed     Abstract available
    
    
    
67. WIEGAND L, Silva P, Noerenberg D, Christen F, et al
    Clonal Hematopoiesis and Lymphoma-Associated Mutations in Hematopoietic Progenitors in B-Cell Non-Hodgkin Lymphoma.
    Blood. 2026 Jan 5:blood.2025030489. doi: 10.1182/blood.2025030489.
    PubMed     Abstract available
    
    
    December 2025
68. ABRAMSON JS, Straus DJ, Bartlett NL, Burke JM, et al
    Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.
    Blood. 2025 Dec 29:blood.2025030190. doi: 10.1182/blood.2025030190.
    PubMed     Abstract available
    
    
    
69. LUAN D, Valid OB, Beyar-Katz O, Tix T, et al
    Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma.
    Blood. 2025 Dec 23:blood.2025031476. doi: 10.1182/blood.2025031476.
    PubMed     Abstract available
    
    
    
70. STALLS JS, Park DC
    Leukemic phase of hepatosplenic T-cell lymphoma.
    Blood. 2025;146:3129.
    PubMed    
    
    
    
71. DESAI SH, Moskowitz AJ, Merryman RW, Shah HR, et al
    PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.
    Blood. 2025 Dec 17:blood.2025030151. doi: 10.1182/blood.2025030151.
    PubMed     Abstract available
    
    
    November 2025
72. 
    Yeung DT, Shanmuganathan N, Reynolds J, et al; Australasian Leukaemia and Lymphoma Group. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study. Blood. 2024;144(19):1993-2001.
    Blood. 2025;146:2729.
    PubMed    
    
    
    
73. HOSOYA H, Bastidas Torres AN, Fernandez-Pol S, Gubatan JM, et al
    Long-term Follow-up of Gastrointestinal CAR T-cell Lymphoma: Homing, Clonal Expansion, and Response to Cyclosporine.
    Blood. 2025 Nov 25:blood.2025031423. doi: 10.1182/blood.2025031423.
    PubMed     Abstract available
    
    
    
74. TAYLOR J
    Big cells, bigger BTK resistance in mantle cell lymphoma.
    Blood. 2025;146:2500-2501.
    PubMed    
    
    
    
75. HU S, Tang G
    Mantle cell lymphoma with KMT2A rearrangement.
    Blood. 2025;146:2491.
    PubMed    
    
    
    
76. FOURNIER B, Latour S
    Methylation profiling: unmasking CAEBV's lymphoma connection.
    Blood. 2025;146:2279-2280.
    PubMed    
    
    
    
77. ELSHARAWI I, Selegean S
    Classic Hodgkin lymphoma with signet ring cell morphology mimicking adenocarcinoma.
    Blood. 2025;146:2370.
    PubMed    
    
    
    
78. JAWOREK CP, Brockelmann PJ
    Feasibility and Safety of Anti-PD1 First-Line Treatment of Classic Hodgkin Lymphoma: Do We See the Full Picture?
    Blood. 2025 Nov 1:blood.2025029935. doi: 10.1182/blood.2025029935.
    PubMed     Abstract available
    
    
    October 2025
79. SHANMUGAM M
    Starving lymphoma with alpha-KG supplementation.
    Blood. 2025;146:2151-2153.
    PubMed    
    
    
    
80. PANDIRI M, Arber DA
    Rare composite of Rosai-Dorfman-Destombes disease and nodular lymphocyte-predominant B-cell (Hodgkin) lymphoma.
    Blood. 2025;146:2272.
    PubMed    
    
    
    
81. RONCERAY L, Huibers MHW, Reutter K, Abla O, et al
    High-grade/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition.
    Blood. 2025 Oct 29:blood.2025031086. doi: 10.1182/blood.2025031086.
    PubMed     Abstract available
    
    
    
82. VAN MEERTEN T, Kersten MJ, Iacoboni G, Hess GR, et al
    Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3.
    Blood. 2025 Oct 29:blood.2025029734. doi: 10.1182/blood.2025029734.
    PubMed     Abstract available
    
    
    
83. VARDHANA SA
    Smarter combos, stronger T cells in lymphoma.
    Blood. 2025;146:1742-1744.
    PubMed    
    
    
    
84. ARMAND P
    Introduction to a review series on follicular lymphoma: solved or insoluble problem?
    Blood. 2025;146:1739-1740.
    PubMed    
    
    
    
85. SHI M, Rech KL
    T-large granular lymphocytic leukemia transformation to peripheral T-cell lymphoma.
    Blood. 2025;146:1868.
    PubMed    
    
    
    September 2025
86. ZUCCA E, Ceriani L, Ciccone G, Di Rocco A, et al
    Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.
    Blood. 2025 Sep 12:blood.2025028823. doi: 10.1182/blood.2025028823.
    PubMed     Abstract available
    
    
    
87. 
    Chavez JC, Dickinson M, Munoz J, et al. Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 2025;145(20):2303-2311.
    Blood. 2025;146:1374.
    PubMed    
    
    
    
88. FALCHI L, Sureda A, Leppa S, Vermaat JS, et al
    Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma.
    Blood. 2025 Sep 8:blood.2025029909. doi: 10.1182/blood.2025029909.
    PubMed     Abstract available
    
    
    
89. HAVRANEK O
    Classic Hodgkin lymphoma: the journey over the destination.
    Blood. 2025;146:1152-1153.
    PubMed    
    
    
    
90. TATTERTON DJ, Newby ML, Allen JD, Sale BJ, et al
    The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B-Cell Lymphoma.
    Blood. 2025 Sep 2:blood.2025029163. doi: 10.1182/blood.2025029163.
    PubMed     Abstract available
    
    
    
91. PAL I, Illendula A, Joyner AM, Manavalan JS, et al
    Nanoromidepsin, a Polymer Nanoparticle of the HDAC Inhibitor, Improves Safety and Efficacy in Models of T-cell Lymphoma.
    Blood. 2025 Sep 2:blood.2024027997. doi: 10.1182/blood.2024027997.
    PubMed     Abstract available
    
    
    August 2025
92. SCHERER F
    Cracking the POD24 code in follicular lymphoma.
    Blood. 2025;146:899-900.
    PubMed    
    
    
    
93. 
    Allo-HCT in Hodgkin lymphoma after CPI.
    Blood. 2025;146:1030.
    PubMed    
    
    
    
94. XU P, Zhu Y, Shi ZY, Wang L, et al
    A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma.
    Blood. 2025 Aug 19:blood.2025028649. doi: 10.1182/blood.2025028649.
    PubMed     Abstract available
    
    
    
95. CASULO C, Sehn LH
    Treatment of Relapsed and Refractory Follicular Lymphoma: Which Treatment for Which Patient for Which Line of Therapy?
    Blood. 2025 Aug 14:blood.2024026018. doi: 10.1182/blood.2024026018.
    PubMed     Abstract available
    
    
    
96. QIU L, Thakral B
    Intrasinusoidal pleomorphic mantle cell lymphoma mimicking intravascular large B-cell lymphoma.
    Blood. 2025;146:897.
    PubMed    
    
    
    
97. REJESKI K, Sanz J, Fei T, Nair MS, et al
    T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy.
    Blood. 2025;146:834-846.
    PubMed     Abstract available
    
    
    
98. SAM J, Leclercq-Cohen G, Gebhardt S, Surowka M, et al
    Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.
    Blood. 2025 Aug 1:blood.2025028863. doi: 10.1182/blood.2025028863.
    PubMed     Abstract available
    
    
    July 2025
99. JAAFAR C, Ethiraj P, Qiu Z, Lin AP, et al
    alpha-Ketoglutarate promotes amino acid depletion and suppresses B-cell lymphoma growth and development.
    Blood. 2025 Jul 23:blood.2024028069. doi: 10.1182/blood.2024028069.
    PubMed     Abstract available
    
    
    
100. WANG W, Cai Q, Liu Y, Nie L, et al
     TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma.
     Blood. 2025 Jul 23:blood.2024026919. doi: 10.1182/blood.2024026919.
     PubMed     Abstract available
     
     
     
101. KITTAI AS, Marchetti M, Al-Sawaf O, Benjamini O, et al
     International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.
     Blood. 2025;146:291-303.
     PubMed     Abstract available
     
     
     
102. ALDERUCCIO JP, Noy A
     The Treatment of Marginal Zone Lymphoma.
     Blood. 2025 Jul 15:blood.2024028269. doi: 10.1182/blood.2024028269.
     PubMed     Abstract available
     
     
     
103. BROOKS TR, Zabor EC, Bedelu Y, Yang X MD, et al
     Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.
     Blood. 2025 Jul 15:blood.2025029117. doi: 10.1182/blood.2025029117.
     PubMed     Abstract available
     
     
     
104. SCARISBRICK JJ, Quaglino P, Whittaker SJ, Bagot M, et al
     A New Prognostic Index (CLIPI) for Advanced Cutaneous Lymphoma Enables Precise Patient Risk Stratification.
     Blood. 2025 Jul 15:blood.2025029628. doi: 10.1182/blood.2025029628.
     PubMed     Abstract available
     
     
     
105. KAULEN LD, Martinez-Lage M, Abramson JS, Karschnia P, et al
     Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy.
     Blood. 2025 Jul 15:blood.2025028964. doi: 10.1182/blood.2025028964.
     PubMed     Abstract available
     
     
     
106. AL JABRI M, Sakhdari A
     A rare phenotype of peripheral T-cell lymphoma, NOS: coexpression of CD15, CD20, and T follicular helper markers in a DUSP22alt case.
     Blood. 2025;146:260.
     PubMed    
     
     
     
107. YANG H, Zhang W, Ravanmehr V, Cui G, et al
     Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement.
     Blood. 2025;146:191-205.
     PubMed     Abstract available
     
     
     
108. PERALES MA, Awan FT, Boumendil A, Patel J, et al
     Outcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis.
     Blood. 2025 Jul 7:blood.2024027197. doi: 10.1182/blood.2024027197.
     PubMed     Abstract available
     
     
     June 2025
109. RAI S, Duns G, Frontzek F, Wong JCH, et al
     Somatic IRF4 Mutations and Thymic Tropism in Primary Mediastinal Large B-cell Lymphoma.
     Blood. 2025 Jun 20:blood.2025028412. doi: 10.1182/blood.2025028412.
     PubMed     Abstract available
     
     
     
110. FREEMAN CL, Srinivasan S, Hodkinson B, Deshpande S, et al
     Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status.
     Blood. 2025;145:3052-3056.
     PubMed     Abstract available
     
     
     
111. MULLER F, Schwingen NR, Hagen M, Scholz JK, et al
     Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma.
     Blood. 2025 Jun 12:blood.2025028375. doi: 10.1182/blood.2025028375.
     PubMed     Abstract available
     
     
     
112. SELVARAJAH S, Xia D
     A small B-cell leukemia/lymphoma with weak to negative expression of CD5.
     Blood. 2025;145:2931.
     PubMed    
     
     
     
113. CLAUDEL A, Cottereau AS, Bachy E, Itti E, et al
     Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.
     Blood. 2025 Jun 11:blood.2024027727. doi: 10.1182/blood.2024027727.
     PubMed     Abstract available
     
     
     
114. HAWKES EA, Gregory GP
     Burkitt lymphoma: click here to add to CAR-T?
     Blood. 2025;145:2678-2680.
     PubMed    
     
     
     
115. TOOZE R, Klein U
     Exploiting tumor-derived IL-10 activity in lymphoma therapy.
     Blood. 2025;145:2676-2678.
     PubMed    
     
     
     
116. KITAGAWA Y, Jaffe ES
     Classic Hodgkin lymphoma in the cerebellum: a rare site for a common disease.
     Blood. 2025;145:2799.
     PubMed    
     
     
     May 2025
117. SHAH B, Nejati R
     Unveiling the enigma: circulating flowerlike large B-lymphoma cells in the context of angioimmunoblastic T-cell lymphoma.
     Blood. 2025;145:2671.
     PubMed    
     
     
     
118. REED HD, Do H, Weller E, Harris MH, et al
     Lymphoid malignancies in patients with Shwachman-Diamond syndrome.
     Blood. 2025;145:2528-2532.
     PubMed     Abstract available
     
     
     
119. TUMULURU S, Godfrey JK, Cooper A, Yu J, et al
     Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response.
     Blood. 2025;145:2460-2472.
     PubMed     Abstract available
     
     
     
120. YOSHIMITSU M, Choi I, Kusumoto S, Shimokawa M, et al
     A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma.
     Blood. 2025 May 15:blood.2024027902. doi: 10.1182/blood.2024027902.
     PubMed     Abstract available
     
     
     
121. PARRY EM, Okosun J
     An Updated Understanding of Follicular Lymphoma Transformation.
     Blood. 2025 May 15:blood.2024026016. doi: 10.1182/blood.2024026016.
     PubMed     Abstract available
     
     
     
122. WANG X, Yi H
     Adult T-cell leukemia/lymphoma coexistent with immune dysregulation-associated EBV+ lymphoproliferative disorder.
     Blood. 2025;145:2396.
     PubMed    
     
     
     
123. PELZL R, Benintende G, Gsottberger F, Scholz JK, et al
     Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.
     Blood. 2025 May 13:blood.2024027877. doi: 10.1182/blood.2024027877.
     PubMed     Abstract available
     
     
     
124. PIROSA MC, Bruscaggin A, Terzi di Bergamo L, Salehi M, et al
     A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNA.
     Blood. 2025 May 13:blood.2024027355. doi: 10.1182/blood.2024027355.
     PubMed     Abstract available
     
     
     
125. 
     Lee HJ, Ramchandren R, Friedman J, et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood. 2025;145(3):290-299.
     Blood. 2025;145:2231.
     PubMed    
     
     
     
126. DU MQ
     EMZL at various sites: learning from each other.
     Blood. 2025;145:2117-2127.
     PubMed     Abstract available
     
     
     
127. PARISI X, Medeiros LJ
     When lymphoma mimics adenocarcinoma: signet ring morphology in follicular lymphoma.
     Blood. 2025;145:2104.
     PubMed    
     
     
     
128. CHAPUY B, Wood T, Stewart C, Dunford A, et al
     DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma.
     Blood. 2025;145:2041-2055.
     PubMed     Abstract available
     
     
     April 2025
129. MARCO-AYALA J, Ortuno FJ
     Appearances deceive: unmasking mantle cell lymphoma with prolymphocytic morphology.
     Blood. 2025;145:1701.
     PubMed    
     
     
     
130. BRODY JD, Jorgensen J, Belada D, Costello R, et al
     Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.
     Blood. 2025;145:1621-1631.
     PubMed     Abstract available
     
     
     
131. STEIDL C
     The immunotherapy real estate of Hodgkin lymphoma.
     Blood. 2025;145:1445-1447.
     PubMed    
     
     
     
132. GOTTSCHLICH A, Grunmeier R, Hoffmann GV, Nandi S, et al
     Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma.
     Blood. 2025;145:1536-1552.
     PubMed     Abstract available
     
     
     
133. TOPP MS, Matasar M, Allan JN, Ansell SM, et al
     Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.
     Blood. 2025;145:1498-1509.
     PubMed     Abstract available
     
     
     March 2025
134. BAKHSHI TJ, Pina-Oviedo S
     Warthin-Finkeldey cells seen in a setting other than measles: chronic lymphocytic leukemia/small lymphocytic lymphoma.
     Blood. 2025;145:1437.
     PubMed    
     
     
     
135. ARAUJO-AYALA F, Beguelin W
     Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics.
     Blood. 2025 Mar 16:blood.2024026020. doi: 10.1182/blood.2024026020.
     PubMed     Abstract available
     
     
     
136. KIM SJ, Lim JQ, Yoon SE, Yang DH, et al
     Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma.
     Blood. 2025 Mar 12:blood.2024027109. doi: 10.1182/blood.2024027109.
     PubMed     Abstract available
     
     
     
137. PRATS-MARTIN C, Morales-Camacho RM
     Prolymphocytic progression of splenic marginal zone lymphoma.
     Blood. 2025;145:1097.
     PubMed    
     
     
     
138. GONZALEZ MANCERA M, Silva O
     ALK+ anaplastic large cell lymphoma expressing CD33 and myeloid nuclear differentiation antigen.
     Blood. 2025;145:1098.
     PubMed    
     
     
     
139. LI W, Wang R, Wang J, Chai D, et al
     Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation.
     Blood. 2025;145:1047-1060.
     PubMed     Abstract available
     
     
     February 2025
140. DI M, Maurer MJ, Flowers CR
     End points and Outcomes in Follicular Lymphoma: What should we measure, how, and why?
     Blood. 2025 Feb 28:blood.2024026978. doi: 10.1182/blood.2024026978.
     PubMed     Abstract available
     
     
     
141. MULVEY E, Rutherford SC, Leonard JP
     The Future of Follicular Lymphoma Management: Strategies on the Horizon.
     Blood. 2025 Feb 28:blood.2024026017. doi: 10.1182/blood.2024026017.
     PubMed     Abstract available
     
     
     
142. NGUYEN VTM, Namba H, Porter H, Shlyueva D, et al
     Synergistic antitumor effect of combined EZH2 and DOT1L inhibition in B-cell lymphoma.
     Blood. 2025 Feb 26:blood.2024026534. doi: 10.1182/blood.2024026534.
     PubMed     Abstract available
     
     
     
143. AL JABRI M, Chang H
     Blastoid variant of double-hit lymphoma masquerading as acute lymphoblastic leukemia.
     Blood. 2025;145:897.
     PubMed    
     
     
     
144. ARMAND P
     Introduction to a review series on mantle cell lymphoma: sands shifting in the darkness.
     Blood. 2025;145:653-654.
     PubMed    
     
     
     
145. JAIN P, Wang M
     High-risk MCL: recognition and treatment.
     Blood. 2025;145:683-695.
     PubMed     Abstract available
     
     
     
146. SILKENSTEDT E, Dreyling M
     Treatment of relapsed/refractory MCL.
     Blood. 2025;145:673-682.
     PubMed     Abstract available
     
     
     
147. SARKOZY C, Tessoulin B, Chiron D
     Unraveling MCL biology to understand resistance and identify vulnerabilities.
     Blood. 2025;145:696-707.
     PubMed     Abstract available
     
     
     
148. LEWIS CS, Barraclough A, Hawkes EA
     Emerging biomarkers for CD3xCD20 bispecific antibodies in lymphoma.
     Blood. 2025 Feb 12:blood.2024025772. doi: 10.1182/blood.2024025772.
     PubMed     Abstract available
     
     
     
149. CHAVEZ JC, Dickinson M, Munoz J, Ulrickson ML, et al
     Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12).
     Blood. 2025 Feb 12:blood.2024027347. doi: 10.1182/blood.2024027347.
     PubMed     Abstract available
     
     
     
150. SAMPLES L, Sadrzadeh H, Frigault MJ, Jacobson CA, et al
     Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma.
     Blood. 2025 Feb 12:blood.2024026831. doi: 10.1182/blood.2024026831.
     PubMed     Abstract available
     
     
     
151. KADY N, Abdelrahman S, Rauf AM, Burgess A, et al
     The GATA-3-dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas.
     Blood. 2025;145:597-611.
     PubMed     Abstract available
     
     
     
152. GARCIA-LACARTE M, Grijalba SC, Melchor Sanchez J, Pascual M, et al
     IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy.
     Blood. 2025 Feb 3:blood.2024025755. doi: 10.1182/blood.2024025755.
     PubMed     Abstract available
     
     
     January 2025
153. BACHY E, Linton K
     Frontline treatment of follicular lymphoma: What will it take to change current practice?
     Blood. 2025 Jan 27:blood.2024026019. doi: 10.1182/blood.2024026019.
     PubMed     Abstract available
     
     
     
154. WANG WJ, Hu Z
     CD5-positive high-grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements.
     Blood. 2025;145:455.
     PubMed    
     
     
     
155. CABALLERO GONZALEZ AC, Ujaldon-Miro C, Pujol-Fernandez P, Montserrat-Torres R, et al
     HSP-CAR30 WITH A HIGH PROPORTION OF LESS-DIFFERENTIATED T CELLS PROMOTES DURABLE RESPONSES IN REFRACTORY CD30+ LYMPHOMA.
     Blood. 2025 Jan 22:blood.2024026758. doi: 10.1182/blood.2024026758.
     PubMed     Abstract available
     
     
     
156. ZHOU T, Elenitoba-Johnson KSJ
     HLA-I aberrations in cutaneous T-cell lymphoma.
     Blood. 2025;145:252-253.
     PubMed    
     
     
     
157. YU W, Li P, Zhou L, Yang M, et al
     A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
     Blood. 2025 Jan 15:blood.2024026401. doi: 10.1182/blood.2024026401.
     PubMed     Abstract available
     
     
     
158. GOBEL C, Niccolai R, de Groot MHP, Jayachandran J, et al
     Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of Diffuse Large B-cell Lymphoma.
     Blood. 2025 Jan 10:blood.2024025500. doi: 10.1182/blood.2024025500.
     PubMed     Abstract available
     
     
     
159. BASKAR S, Peng H, Gaglione EM, Carstens EJ, et al
     Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragment covalently deposited on lymphoma cells.
     Blood. 2025 Jan 7:blood.2024024846. doi: 10.1182/blood.2024024846.
     PubMed     Abstract available
     
     
     December 2024
160. NAHARRO EF, Linden MA
     Auer rod-like inclusions in B-cell lymphoma mimicking therapy-related acute myeloid leukemia.
     Blood. 2024;144:2793.
     PubMed    
     
     
     
161. YENWONGFAI LN, Francischetti IMB
     Prominent expansion of EBV+ large B cells obscuring follicular helper T-cell lymphoma.
     Blood. 2024;144:2682.
     PubMed    
     
     
     
162. SEHN LH, Hallek M
     Introduction to a review series on high-risk aggressive lymphoma.
     Blood. 2024;144:2561-2562.
     PubMed    
     
     
     
163. DAVIES AJ
     The high-grade B-cell lymphomas: double hit and more.
     Blood. 2024;144:2583-2592.
     PubMed     Abstract available
     
     
     
164. ROSCHEWSKI M, Phelan JD, Jaffe ES
     Primary large B-cell lymphomas of immune-privileged sites.
     Blood. 2024;144:2593-2603.
     PubMed     Abstract available
     
     
     
165. DABROWSKA-IWANICKA A, Nowakowski GS
     DLBCL: who is high risk and how should treatment be optimized?
     Blood. 2024;144:2573-2582.
     PubMed     Abstract available
     
     
     
166. 
     Flavell JR, Baumforth KRN, Wood VHJ, et al. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus-encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood. 2008;111(1):292-301.
     Blood. 2024;144:2559.
     PubMed    
     
     
     
167. LEE HJ, Ramchandren R, Friedman J, Melear JM, et al
     Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma.
     Blood. 2024 Dec 2:blood.2024024681. doi: 10.1182/blood.2024024681.
     PubMed     Abstract available
     
     
     November 2024
168. IACOBONI G, Morschhauser F
     Building the Future Management of Follicular Lymphoma with T-Cell-Redirecting Strategies.
     Blood. 2024 Nov 14:blood.2024025699. doi: 10.1182/blood.2024025699.
     PubMed     Abstract available
     
     
     
169. CHEVALIER S, Legrand C
     B-cell acute lymphoblastic leukemia with MEF2D::BCL9 rearrangement mimicking a Burkitt lymphoma.
     Blood. 2024;144:2067.
     PubMed    
     
     
     October 2024
170. IQBAL J, Inghirami G, Chan WC
     New insights into the biology of T-cell lymphomas.
     Blood. 2024;144:1873-1886.
     PubMed     Abstract available
     
     
     
171. DE LEVAL L, Gaulard P, Dogan A
     A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas.
     Blood. 2024;144:1855-1872.
     PubMed     Abstract available
     
     
     
172. MARCHI E, Craig JW, Kalac M
     Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL).
     Blood. 2024;144:1898-1909.
     PubMed     Abstract available
     
     
     
173. MOSKOWITZ AJ, Stuver RN, Horwitz SM
     Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs).
     Blood. 2024;144:1887-1897.
     PubMed     Abstract available
     
     
     
174. SEHN LH, Bartlett NL, Matasar MJ, Schuster SJ, et al
     Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after >/=2 prior therapies.
     Blood. 2024 Oct 24:blood.2024025454. doi: 10.1182/blood.2024025454.
     PubMed     Abstract available
     
     
     
175. ALDUAIJ W, Jiang A, Villa D, Collinge BJ, et al
     CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL.
     Blood. 2024 Oct 23:blood.2024025725. doi: 10.1182/blood.2024025725.
     PubMed     Abstract available
     
     
     
176. KUMAR A, Soumerai JD, Abramson JS, Barnes JA, et al
     Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation.
     Blood. 2024 Oct 22:blood.2024025563. doi: 10.1182/blood.2024025563.
     PubMed     Abstract available
     
     
     
177. HU J, Dunbar CE
     T-Cell Lymphomas in Recipients of CAR-T Cells: Assessing Risks and Causalities.
     Blood. 2024 Oct 11:blood.2024025828. doi: 10.1182/blood.2024025828.
     PubMed     Abstract available
     
     
     
178. KWANG AC, Duran GE, Fernandez-Pol S, Najidh S, et al
     Genetic alteration of class I HLA in cutaneous T-cell lymphoma.
     Blood. 2024 Oct 10:blood.2024024817. doi: 10.1182/blood.2024024817.
     PubMed     Abstract available
     
     
     
179. ALIG SK
     FISHing for clarity in double-hit lymphomas.
     Blood. 2024;144:1550-1552.
     PubMed    
     
     
     
180. 
     Friedberg JW, Bordoni R, Patel-Donnelly D, et al. Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood. 2024;143(9):786-795.
     Blood. 2024;144:1647.
     PubMed    
     
     
     
181. COLLINGE B, Ben-Neriah S, Hilton LK, Alduaij W, et al
     Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH-BCL2.
     Blood. 2024;144:1611-1616.
     PubMed     Abstract available
     
     
     
182. LAURENT C, Trisal P, Tesson B, Seth S, et al
     Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance.
     Blood. 2024 Oct 7:blood.2024024496. doi: 10.1182/blood.2024024496.
     PubMed     Abstract available
     
     
     
183. WALLACE DS, Loh KP, Casulo C
     How I Treat Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
     Blood. 2024 Oct 2:blood.2024024788. doi: 10.1182/blood.2024024788.
     PubMed     Abstract available
     
     
     September 2024
184. POCOCK R, Mansour MR
     T-ALL and T-LBL: a notch apart.
     Blood. 2024;144:1356-1357.
     PubMed    
     
     
     
185. TABATA R, Matsue K
     ALK-positive anaplastic large cell lymphoma, Hodgkin-like pattern with unexplained fever.
     Blood. 2024;144:1460.
     PubMed    
     
     
     
186. QUALLS DA, Armand P, Salles GA
     The current landscape of frontline large B-cell lymphoma trials.
     Blood. 2024 Sep 24:blood.2023023789. doi: 10.1182/blood.2023023789.
     PubMed     Abstract available
     
     
     
187. 
     Laurent C, Dietrich S, Tarte K. Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm. Blood. 2024;143(12):1080-1090.
     Blood. 2024;144:1349.
     PubMed    
     
     
     
188. 
     Hill LC, Rouce RH, Wu MJ, et al. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024;143(13):1231-1241.
     Blood. 2024;144:1349.
     PubMed    
     
     
     
189. ABRO B, Maurer MJ, Habermann TM, Burack R, et al
     Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO Cohort Study analysis.
     Blood. 2024 Sep 10:blood.2024025681. doi: 10.1182/blood.2024025681.
     PubMed     Abstract available
     
     
     
190. MAURER K, Grabski IN, Houot R, Gohil SH, et al
     Baseline Immune State and T-cell Clonal Kinetics are Associated with Durable Response to CAR-T Therapy in Large B-cell Lymphoma.
     Blood. 2024 Sep 6:blood.2024024381. doi: 10.1182/blood.2024024381.
     PubMed     Abstract available
     
     
     August 2024
191. ZHOU Q, Chang H
     Circulating composite B- and T-cell lymphoma.
     Blood. 2024;144:1027.
     PubMed    
     
     
     
192. WALLACE DS, Barr PM
     Ready, AIM, stop: ibrutinib plus venetoclax in MCL.
     Blood. 2024;144:800-802.
     PubMed    
     
     
     
193. BHATLA T, Hogan L MD, Teachey DT, Bautista F, et al
     Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: DELPHINUS Study.
     Blood. 2024 Aug 16:blood.2024024493. doi: 10.1182/blood.2024024493.
     PubMed     Abstract available
     
     
     
194. PABST T, Bacher U
     Boosting CAR T cells against lymphomas.
     Blood. 2024;144:689-691.
     PubMed    
     
     
     
195. CHANG CA, Emberley E, D'Souza AL, Zhao W, et al
     ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies.
     Blood. 2024;144:757-770.
     PubMed     Abstract available
     
     
     
196. WANG T, Silva O
     HHV-8+ diffuse large B-cell lymphoma with EBV coinfection occurring posttransplant.
     Blood. 2024;144:677.
     PubMed    
     
     
     
197. NIE J, Wang C, Zheng L, Liu Y, et al
     Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma.
     Blood. 2024 Aug 2:blood.2024024487. doi: 10.1182/blood.2024024487.
     PubMed     Abstract available
     
     
     
198. KUPPERS R
     MYC translocation architecture in B-NHL.
     Blood. 2024;144:469-471.
     PubMed    
     
     
     
199. ARAFAT S, Don M
     A case of Richter transformation to diffuse large B-cell lymphoma with aberrant T-cell marker expression.
     Blood. 2024;144:586.
     PubMed    
     
     
     July 2024
200. TE VRUGT M, Wessolowski JS, Randau G, Alfert A, et al
     Pediatric T-cell lymphoblastic lymphoma but not leukemia harbor TRB::NOTCH1 fusions with unfavorable outcome.
     Blood. 2024 Jul 18:blood.2024025307. doi: 10.1182/blood.2024025307.
     PubMed     Abstract available
     
     
     
201. RYAN CE, Cohen JB
     Is rituximab retro in mantle cell lymphoma?
     Blood. 2024;144:241-243.
     PubMed    
     
     
     
202. NABEEL H, Bhagat G
     Double-hit, double-expressor follicular lymphoma with plasmacytic differentiation.
     Blood. 2024;144:339.
     PubMed    
     
     
     
203. 
     Armand P, Zinzani PL, Lee HJ, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023;142(10):878-886.
     Blood. 2024;144:341.
     PubMed    
     
     
     
204. PICCALUGA PP
     SOX11 in EBV-negative Burkitt lymphoma.
     Blood. 2024;144:128-129.
     PubMed    
     
     
     
205. FALINI B, Lazzi S
     Mantle cell lymphoma with IRTA1+ reactive expansion of the marginal zone.
     Blood. 2024;144:237.
     PubMed    
     
     
     June 2024
206. LUCENA LAGE S, Ramaswami R, Rocco J, Rupert A, et al
     Inflammasome activation in patients with Kaposi sarcoma herpesvirus (KSHV)-associated disorders.
     Blood. 2024 Jun 28:blood.2024024144. doi: 10.1182/blood.2024024144.
     PubMed     Abstract available
     
     
     
207. BIDOT S, Feldman AL
     Herpetic lymphadenitis mimicking Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.
     Blood. 2024;143:2808.
     PubMed    
     
     
     
208. FLAIFEL A, Rocco JM
     HHV-6 lymphadenitis with DRESS syndrome: another lymphoma mimic.
     Blood. 2024;143:2671.
     PubMed    
     
     
     
209. CHRISMAN LP, Trimark PF, Pang Y, Pease DR, et al
     Updated cutaneous T-cell lymphoma TNMB staging criteria fail to identify Sezary syndrome patients with low blood burden.
     Blood. 2024 Jun 7:blood.2023023584. doi: 10.1182/blood.2023023584.
     PubMed     Abstract available
     
     
     May 2024
210. SMITH MR, Jegede O, Martin P, Till B, et al
     Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma.
     Blood. 2024 May 31:blood.2024023962. doi: 10.1182/blood.2024023962.
     PubMed     Abstract available
     
     
     
211. APAYDIN ARIKAN E, Jaffe ES
     Mantle cell lymphoma with marked plasmacytic differentiation: two contrasting faces.
     Blood. 2024;143:2337.
     PubMed    
     
     
     
212. BRINKMANN BJ, Floerchinger A, Schniederjohann C, Roider T, et al
     CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
     Blood. 2024 May 28:blood.2023022682. doi: 10.1182/blood.2023022682.
     PubMed     Abstract available
     
     
     
213. JAIN P, Jelloul FZ
     Biclonal mantle cell lymphoma.
     Blood. 2024;143:2217.
     PubMed    
     
     
     
214. GUPTA M, Bradley J, Massaad E, Burns E, et al
     Rapid Tumor DNA Analysis of Cerebrospinal Fluid Accelerates Treatment of Central Nervous System Lymphoma.
     Blood. 2024 May 22:blood.2024023832. doi: 10.1182/blood.2024023832.
     PubMed     Abstract available
     
     
     
215. MALINVERNI C, Bernardelli A, Glimelius I, Mirandola M, et al
     Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
     Blood. 2024 May 16:blood.2023023525. doi: 10.1182/blood.2023023525.
     PubMed     Abstract available
     
     
     
216. 
     MRD and EFS in pediatric T-lymphoblastic lymphoma.
     Blood. 2024;143:2111.
     PubMed    
     
     
     
217. 
     Silva A, Almeida ARM, Cachucho A, et al. Overexpression of wild-type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood. 2021;138(12):1040-1052.
     Blood. 2024;143:2108-2110.
     PubMed    
     
     
     
218. YUAN CT, Ma WL
     Transformed mantle cell lymphoma with additional triple-hit genotypes can be resistant to a Bruton tyrosine kinase inhibitor.
     Blood. 2024;143:2106.
     PubMed    
     
     
     
219. RIBERA JM
     MRD: also for T-lymphoblastic lymphoma.
     Blood. 2024;143:2017-2019.
     PubMed    
     
     
     
220. HILTON LK, Collinge BJ, Ben-Neriah S, Alduaij W, et al
     Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study.
     Blood. 2024 May 3:blood.2024024251. doi: 10.1182/blood.2024024251.
     PubMed     Abstract available
     
     
     
221. KIM J, Cho J, Lee MH, Yoon SE, et al
     Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis.
     Blood. 2024 May 2:blood.2023023419. doi: 10.1182/blood.2023023419.
     PubMed     Abstract available
     
     
     
222. ARORA J, Ayyappan S, Yin C, Smith BJ, et al
     T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC.
     Blood. 2024;143:1816-1824.
     PubMed     Abstract available
     
     
     April 2024
223. SARKOZY C, Callanan MB, Thieblemont C, Oberic L, et al
     Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients.
     Blood. 2024 Apr 26:blood.2024023944. doi: 10.1182/blood.2024023944.
     PubMed     Abstract available
     
     
     
224. HANDUNNETTI SM, Anderson MA, Burbury KI, Thompson PA, et al
     Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
     Blood. 2024 Apr 25:blood.2023023388. doi: 10.1182/blood.2023023388.
     PubMed     Abstract available
     
     
     
225. CROCHET G, Iacoboni G, Couturier A, Bachy E, et al
     Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
     Blood. 2024 Apr 24:blood.2024024526. doi: 10.1182/blood.2024024526.
     PubMed     Abstract available
     
     
     
226. MAYBURY BD, James LJ BSc (Hons), Phillips N, Venkatadasari I, et al
     Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival.
     Blood. 2024 Apr 22:blood.2024024048. doi: 10.1182/blood.2024024048.
     PubMed     Abstract available
     
     
     
227. LOCKE FL, Siddiqi T, Jacobson CA, Ghobadi A, et al
     Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity.
     Blood. 2024 Apr 18:blood.2023023447. doi: 10.1182/blood.2023023447.
     PubMed     Abstract available
     
     
     
228. SUREDA-GOMEZ M, Iaccarino I, De Bolos A, Meyer MA, et al
     SOX11 expression is restricted to EBV-negative Burkitt lymphoma and associates with molecular genetic features.
     Blood. 2024 Apr 15:blood.2023023242. doi: 10.1182/blood.2023023242.
     PubMed     Abstract available
     
     
     
229. MERLIO JP
     Staphylococcus aureus and Sezary syndrome.
     Blood. 2024;143:1436-1438.
     PubMed    
     
     
     
230. WEI Q, Bueso-Ramos CE
     Thymoma with aberrant expression of CD20: a potential diagnostic pitfall of B-cell lymphoma.
     Blood. 2024;143:1551.
     PubMed    
     
     
     
231. VADIVEL CK, Willerslev-Olsen A, Namini MRJ, Zeng Z, et al
     Staphylococcus aureus induces drug resistance in cancer T cells in Sezary syndrome.
     Blood. 2024;143:1496-1512.
     PubMed     Abstract available
     
     
     
232. KROEZE E, Iaccarino I, Kleisman MM, Mondal M, et al
     Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma.
     Blood. 2024 Apr 8:blood.2024023938. doi: 10.1182/blood.2024023938.
     PubMed     Abstract available
     
     
     
233. MARCAIS A
     Targeting PD-L1 to treat ATLL?
     Blood. 2024;143:1320-1322.
     PubMed    
     
     
     
234. LOCKE FL, Oluwole OO, Kuruvilla J, Thieblemont C, et al
     Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.
     Blood. 2024 Apr 1:blood.2023021620. doi: 10.1182/blood.2023021620.
     PubMed     Abstract available
     
     
     March 2024
235. GROVER NS, Beaven AW
     T-cell lymphoma: the CAR-T revolution is coming.
     Blood. 2024;143:1201-1202.
     PubMed    
     
     
     
236. GIESSINGER J, Pullarkat ST
     An unusual presentation of lymphoplasmacytic lymphoma with isolated brachial plexus infiltration and amyloidosis.
     Blood. 2024;143:1315.
     PubMed    
     
     
     
237. 
     Zinzani PL, Thieblemont C, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142(2):141-145.
     Blood. 2024;143:1316.
     PubMed    
     
     
     
238. HILL LC, Rouce RH, Wu MJ, Wang T, et al
     Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas.
     Blood. 2024;143:1231-1241.
     PubMed     Abstract available
     
     
     
239. STEIDL C, Stevenson FK
     Introduction to a review series on the influence of the tumor microenvironment on the pathogenesis of B-cell lymphomas.
     Blood. 2024;143:1057-1058.
     PubMed    
     
     
     
240. RYAN CE, Armand P, LaCasce AS
     Frontline Treatment of Mantle Cell Lymphoma.
     Blood. 2024 Mar 18:blood.2023022352. doi: 10.1182/blood.2023022352.
     PubMed     Abstract available
     
     
     
241. GODFREY JK, Gao L, Shouse G, Song JY, et al
     Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.
     Blood. 2024 Mar 14:blood.2024024168. doi: 10.1182/blood.2024024168.
     PubMed     Abstract available
     
     
     
242. MOLIN D
     Aging Kairos: treating older Hodgkin patients.
     Blood. 2024;143:943-945.
     PubMed    
     
     
     
243. EL HUSSEIN S
     Monomorphic epitheliotropic T-cell lymphoma with strong CD4 expression.
     Blood. 2024;143:1055.
     PubMed    
     
     
     
244. HAYASHI RJ, Hermiston ML, Wood BL, Teachey DT, et al
     MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's Oncology Group Trial AALL1231.
     Blood. 2024 Mar 8:blood.2023021184. doi: 10.1182/blood.2023021184.
     PubMed     Abstract available
     
     
     
245. AHMED R, Feldman AL
     Occult ALK-negative anaplastic large cell lymphoma complicating chronic lymphocytic leukemia.
     Blood. 2024;143:938.
     PubMed    
     
     
     February 2024
246. SCHUSTER SJ, Huw LY, Bolen CR, Maximov V, et al
     Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
     Blood. 2024;143:822-832.
     PubMed     Abstract available
     
     
     
247. FRIEDBERG JW, Bordoni R, Patel-Donnelly D, Larson T, et al
     Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
     Blood. 2024;143:786-795.
     PubMed     Abstract available
     
     
     
248. OLSZEWSKI AJ
     When B cells rebuff bispecifics.
     Blood. 2024;143:744-746.
     PubMed    
     
     
     
249. LYNCH RC
     Toward a cure for cHL without chemotherapy.
     Blood. 2024;143:741-742.
     PubMed    
     
     
     
250. ANG Z, Thomas-Tikhonenko A
     Lymphoma immunotherapy: the garden of forking paths.
     Blood. 2024;143:655-657.
     PubMed    
     
     
     
251. SCHOOLCRAFT DK, Karrs JX
     Flower cell morphology in high-grade B-cell lymphoma of the maxillary sinus.
     Blood. 2024;143:738.
     PubMed    
     
     
     
252. BOARDMAN AP, Palomba ML
     Does BTKi improve CAR T-cell therapy in MCL?
     Blood. 2024;143:653-655.
     PubMed    
     
     
     
253. TONINO SH, Kersten MJ
     The quest for a cure in follicular lymphoma.
     Blood. 2024;143:475-476.
     PubMed    
     
     
     
254. WINTER JN, Ferreri AJM
     Predicting outcomes in CNS lymphoma with ctDNA.
     Blood. 2024;143:478-480.
     PubMed    
     
     
     
255. HEGER JM, Mattlener J, Schneider J, Godel P, et al
     Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA.
     Blood. 2024;143:522-534.
     PubMed     Abstract available
     
     
     
256. CASULO C
     How do you define treatment success in MZL?
     Blood. 2024;143:382-383.
     PubMed    
     
     
     
257. DARNELL EP, Frigault MJ
     Two years later: CD19 CAR-T going the distance.
     Blood. 2024;143:379-380.
     PubMed    
     
     
     
258. GANDHI MK, Kelly GL
     EBNA2: a viral maestra conducting a symphony orchestra.
     Blood. 2024;143:384-385.
     PubMed    
     
     
     January 2024
259. MORSY MHA, Lilienthal I, Lord M, Merrien M, et al
     SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
     Blood. 2024 Jan 18:blood.2023022241. doi: 10.1182/blood.2023022241.
     PubMed     Abstract available
     
     
     
260. MORSY MHA, Lilienthal I, Lord M, Merrien M, et al
     SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
     Blood. 2024;143:1953-1964.
     PubMed     Abstract available
     
     
     
261. CERCHIETTI L
     Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B cell lymphoma.
     Blood. 2024 Jan 11:blood.2023021002. doi: 10.1182/blood.2023021002.
     PubMed     Abstract available
     
     
     
262. COPPO P, Ricard L
     Plasmablastic lymphoma: better refine prognosis.
     Blood. 2024;143:101-102.
     PubMed    
     
     
     
263. DREYLING M, Fowler NH, Dickinson M, Martinez-Lopez J, et al
     Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update.
     Blood. 2024 Jan 9:blood.2023021567. doi: 10.1182/blood.2023021567.
     PubMed     Abstract available
     
     
     
264. RADTKE A, Roschewski M
     The follicular lymphoma tumor microenvironment at single cell and spatial resolution.
     Blood. 2024 Jan 9:blood.2023020999. doi: 10.1182/blood.2023020999.
     PubMed     Abstract available
     
     
     December 2023
265. BARRACLOUGH A, Hawkes EA
     Tribulations of trials in aggressive lymphoma.
     Blood. 2023;142:2232-2234.
     PubMed    
     
     
     
266. VEELKEN H
     Energy overpowers sweet tooth in FL.
     Blood. 2023;142:2226-2229.
     PubMed    
     
     
     
267. CHIBA M, Shimono J, Suto K, Ishio T, et al
     Whole genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in Adult T-cell leukemia/lymphoma.
     Blood. 2023 Dec 24:blood.2023021423. doi: 10.1182/blood.2023021423.
     PubMed     Abstract available
     
     
     
268. SHEA L, Mehta-Shah N
     Peripheral T-cell lymphoma: Are all patients high-risk?
     Blood. 2023 Dec 24:blood.2023020912. doi: 10.1182/blood.2023020912.
     PubMed     Abstract available
     
     
     
269. FU L, Gong S
     KMT2A-rearranged B-lymphoblastic leukemia/lymphoma with surface light chain restriction and lacking immature markers.
     Blood. 2023;142:2220.
     PubMed    
     
     
     
270. LAURENT C, Dietrich S, Tarte K
     Cell crosstalk within lymphoma tumor microenvironment: follicular lymphoma as a paradigm.
     Blood. 2023 Dec 14:blood.2023021000. doi: 10.1182/blood.2023021000.
     PubMed     Abstract available
     
     
     
271. SPAARGAREN M
     What's brewing for MALT1 in lymphoma?
     Blood. 2023;142:1939-1941.
     PubMed    
     
     
     
272. LUU BE, Xu SA
     A peculiar case of cyclin D1-positive lymphoplasmacytic lymphoma.
     Blood. 2023;142:2034.
     PubMed    
     
     
     
273. WIMBERGER N, Ober F, Avar G, Grau M, et al
     Oncogene-induced MALT1 protease activity drives posttranscriptional gene expression in malignant lymphomas.
     Blood. 2023;142:1985-2001.
     PubMed     Abstract available
     
     
     November 2023
274. RAUERT-WUNDERLICH H
     EGR1 changes course in B-cell lymphoma.
     Blood. 2023;142:1850-1851.
     PubMed    
     
     
     
275. CAI J, Lee J
     Cold agglutinin syndrome with unexpected bone marrow CD5+ diffuse large B-cell lymphoma.
     Blood. 2023;142:1935.
     PubMed    
     
     
     
276. ALDERUCCIO JP, Nayak L, Cwynarski K
     How I treat secondary CNS involvement by aggressive lymphomas.
     Blood. 2023;142:1771-1783.
     PubMed     Abstract available
     
     
     
277. STEVENSON FK PROFESSOR, Forconi F
     The essential microenvironmental role of oligomannoses inserted into the antigen-binding sites of lymphoma cells.
     Blood. 2023 Nov 22:blood.2023022703. doi: 10.1182/blood.2023022703.
     PubMed     Abstract available
     
     
     
278. GHESQUIERES H, Krzisch D, Nicolas Virelizier E, Kanoun S, et al
     Phase 2 LYSA study of prednisone, vinblastine, doxorubicin, bendamustine for untreated older Hodgkin lymphoma patients.
     Blood. 2023 Nov 18:blood.2023021564. doi: 10.1182/blood.2023021564.
     PubMed     Abstract available
     
     
     
279. DUELL J, Leipold AM, Appenzeller S, Fuhr V, et al
     Sequential Antigen-loss and Branching Evolution in Lymphoma after CD19- and CD20-Targeted T-cell Redirecting Therapy.
     Blood. 2023 Nov 17:blood.2023021672. doi: 10.1182/blood.2023021672.
     PubMed     Abstract available
     
     
     
280. MURAKAMI MA
     Toward rational therapy for mantle cell lymphoma.
     Blood. 2023;142:1504-1506.
     PubMed    
     
     
     
281. ETANCELIN P, Boussaid I
     Two sides of the same coin: transdifferentiation from Burkitt lymphoma to histiocytic sarcoma.
     Blood. 2023;142:1576.
     PubMed    
     
     
     October 2023
282. ABRAMSON JS, Palomba ML, Gordon LI, Lunning MA, et al
     Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
     Blood. 2023 Oct 27:blood.2023020854. doi: 10.1182/blood.2023020854.
     PubMed     Abstract available
     
     
     
283. MINSON AG, Hamad N, Cheah CY, Tam CS, et al
     CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study.
     Blood. 2023 Oct 26:blood.2023021306. doi: 10.1182/blood.2023021306.
     PubMed     Abstract available
     
     
     
284. BROCKELMANN PJ
     AXL-erating mantle cell lymphoma treatment.
     Blood. 2023;142:1411-1412.
     PubMed    
     
     
     
285. GINI G, Tani M, Tucci A, Marcheselli L, et al
     Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study.
     Blood. 2023;142:1438-1447.
     PubMed     Abstract available
     
     
     
286. NEELAPU SS, Chavez JC, Sehgal A, Epperla N, et al
     Three-Year Follow-Up Analysis of Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5).
     Blood. 2023 Oct 25:blood.2023021243. doi: 10.1182/blood.2023021243.
     PubMed     Abstract available
     
     
     
287. COLLINS GP
     Tackling PD1i resistance in Hodgkin lymphoma.
     Blood. 2023;142:1333-1334.
     PubMed    
     
     
     
288. BELADA D, Kopeckova K, Bergua Burgues JM, Stevens D, et al
     Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
     Blood. 2023;142:1348-1358.
     PubMed     Abstract available
     
     
     
289. LEOPIZZI M, Mundo L, Messina E, Campolo F, et al
     Epstein-Barr virus encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma.
     Blood. 2023 Oct 17:blood.2023021346. doi: 10.1182/blood.2023021346.
     PubMed     Abstract available
     
     
     
290. DI CIACCIO PR, Polizzotto MN, Cwynarski K, Gerrie AS, et al
     The Influence of Immunodeficiency, Disease Features and Patient Characteristics on Survival in Plasmablastic Lymphoma.
     Blood. 2023 Oct 13:blood.2023021348. doi: 10.1182/blood.2023021348.
     PubMed     Abstract available
     
     
     
291. BOMMIER C, Zucca E, Chevret S, Conconi A, et al
     Early Complete Response as Validated Surrogate Marker in Extranodal Marginal Zone Lymphoma Systemic Therapy.
     Blood. 2023 Oct 6:blood.2023020984. doi: 10.1182/blood.2023020984.
     PubMed     Abstract available
     
     
     
292. RUSSLER-GERMAIN DA, Cliff ERS, Bartlett NL
     Cell-of-Origin Effect of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma: No Ordinary Subgroup Analysis.
     Blood. 2023 Oct 5:blood.2023022048. doi: 10.1182/blood.2023022048.
     PubMed     Abstract available
     
     
     
293. 
     Jain MD, Ziccheddu B, Coughlin CA, et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 2022;140(5):491-503.
     Blood. 2023;142:1255.
     PubMed    
     
     
     
294. MANDATO E, Yan Q, Ouyang J, Paczkowska J, et al
     MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8.
     Blood. 2023;142:1219-1232.
     PubMed     Abstract available
     
     
     September 2023
295. 
     Balsas P, Veloza L, Clot G, et al. SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma. Blood. 2021;138(22):2202-2215.
     Blood. 2023;142:1173-1176.
     PubMed    
     
     
     
296. NARITA K, Takeuchi K
     FISH for EBV genome in a patient with diffuse large B-cell lymphoma harboring t(14;18)(q32;q21).
     Blood. 2023;142:1172.
     PubMed    
     
     
     
297. ZHOU N, Busino L
     Targeting epigenetics and ferroptosis in DLBCL.
     Blood. 2023;142:1108-1109.
     PubMed    
     
     
     
298. DIEPSTRA A, Nolte IM, van den Berg A, Magpantay LI, et al
     Elevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years.
     Blood. 2023 Sep 25:blood.2023020959. doi: 10.1182/blood.2023020959.
     PubMed     Abstract available
     
     
     
299. LIU Y, Kimpara S, Hoang NM, Daenthanasanmak A, et al
     EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B cell lymphoma.
     Blood. 2023 Sep 22:blood.2023020142. doi: 10.1182/blood.2023020142.
     PubMed     Abstract available
     
     
     
300. QUALLS DA, Lambert N, Caimi PF, Merrill MH, et al
     Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes in a multicenter retrospective study.
     Blood. 2023 Sep 22:blood.2023021274. doi: 10.1182/blood.2023021274.
     PubMed     Abstract available
     
     
     
301. FREEMAN CL, Locke FL
     CARs put age in the rearview mirror.
     Blood. 2023;142:1029-1031.
     PubMed    
     
     
     
302. 
     Williams AM, Salehabadi SM, Xing M, et al. Modifiable risk factors for neurocognitive and psychosocial problems after Hodgkin lymphoma. Blood. 2022;139(20):3073-3086.
     Blood. 2023;142:1028.
     PubMed    
     
     
     
303. ZHOU N, Choi J, Grothusen G, Kim BJ, et al
     DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.
     Blood. 2023;142:973-988.
     PubMed     Abstract available
     
     
     
304. HAEBE SE, Day G, Czerwinski DK, Sathe A, et al
     Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B cell receptor.
     Blood. 2023 Sep 8:blood.2023020360. doi: 10.1182/blood.2023020360.
     PubMed     Abstract available
     
     
     
305. CHEAH CY
     Pembrolizumab: a key for some, but not all, HL.
     Blood. 2023;142:861-862.
     PubMed    
     
     
     
306. 
     Panea RI, Love CL, Shingleton JR, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134(19):1598-1607.
     Blood. 2023;142:940.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum